



Origination:	10/6/2016
Last Approved:	7/16/2019
Last Revised:	10/6/2016
Next Review:	7/15/2022
Owner:	<i>Erin Eicke: Abilene Market Director, Surgical Services</i>
Policy Area:	<i>Surgical Services</i>
Standards & Regulations:	
References:	

## Surgery and Dual Anti-Platelet Therapy (DAPT) After Coronary Stent, 4.6666

### PURPOSE:

Advances in stents for coronary artery disease have resulted in a revision of national guidelines regarding how DAPT should be held to facilitate surgery. The components of DAPT include Aspirin plus a P2Y12 inhibitor such as Plavix (clopidogrel), Brilinta (ticagrelor), or Effient (prasugrel). For the purposes of this policy it is assumed that Aspirin will be continued throughout the peri-operative time period and cessation/resumption of DAPT indicates modifications to the P2Y12 inhibitor.

### POLICY:

#### For any Patient on DAPT for a coronary stent:

Is the Surgery necessary to prevent a life or Limb Threatening surgery?

Yes - Document the emergent nature of the procedure and proceed with surgery.

No - Continue below

Is the stent a Bare Metal Stent?

Yes - Surgery may proceed at 30 days from time of placement.

No - Continue below

Is the Surgery a time sensitive surgery intended to prevent significant morbidity?

Yes - Document the time-sensitive nature of the procedure and proceed with surgery at 3 months. Consider maintaining current DAPT regimen if not contraindicated for intended procedure. Consider using an IV anti-platelet bridge in consultation with the patient's cardiologist.

No - Continue below

For stents placed over 6 months prior to the surgery, the surgeon should determine necessity of stopping DAPT for the intended procedure. Orders to discontinue DAPT prior to the operation and resume DAPT after the operation will be the responsibility of the surgeon.

## Attachments

No Attachments

## Approval Signatures

Approver	Date
Tracey Carrigan: Director, Surgical Services	7/16/2019
Heather Hess: Nurse Manager, Nursing	7/16/2019

COPY